Common antifungal drug may help prevent esophageal cancer recurrence
NCT ID NCT05609253
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial investigates whether itraconazole, a common antifungal medication, can reduce the risk of cancer in people with high-risk Barrett's esophagus who have already undergone endoscopic ablation. Barrett's esophagus often returns after treatment, increasing the chance of esophageal cancer. The study will measure drug levels in blood and tissue, and check for side effects, in 10 participants.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Itraconazole
- What this could lead to
- If it works, this could point toward a way to prevent Barrett's esophagus from coming back after treatment, lowering the risk of esophageal cancer.
- What could go wrong
- This is a very early, small study (10 people) focused on drug levels and safety, not yet on preventing recurrence. Itraconazole also has side effects and may not prove effective in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
10 people
The number who actually took part.
- Started
-
Sep 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with Barrett's esophagus with either confirmed low-grade dysplasia or high grade dysplasia or intramucosal/T1 adenocarcinoma (see histologic review) being considered for endoscopic treatment. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 Exclusion Criteria: * Inability to provide informed consent, New York Heart Association class III or IV congestive heart failure (CHF), liver function tests (LFT)\>3X upper limit of normal, drug allergy to itraconazole, pregnancy, prolonged QTc (\>450 ms for men and QTc\>470 ms for women) or critical drug interactions with other medications metabolized by cytochrome P450(CYP)3A4.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Barrett oesophagitis with dysplasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.